engleski

AGE Containing Immune Complexes in Diabetic and Nondiabetic Patients with Coronary Artery Disease

Advanced glycation endproducts (AGE) and anti-AGE antibodies in free and immune complex bound form were assayed in serum of diabetic (n=69) and nondiabetic (n=78) patients with coronary artery disease (CAD), and of control subjects (n=47) free from vascular disease. Blocking ELISA was used to test immunoreactivity against AGE epitope(s), and competitive ELISA to measure total AGE content. Immune complexes containing AGE moiety was detected by ELISA using an immunochemical bridge and soluble AGE-IC were precipitated from serum by polyethylene glycol and analysed. Anti-AGE immunoreactivity was significantly (p<0.05) higher in diabetic than in control subjects. Although great dispersion of anti-AGE antibody titre was observed in nondiabetic CAD patients, the difference did not reach statistical significance from control subjects. Both diabetic and nondiabetic CAD patients had a higher level of circulating immune complexes containing AGE moiety as antigen than control subjects (p<0.01). Study patients showed positive correlation between serum AGE level and AGE-immune complexes (DM+CAD: r=0.3, p<0.01 ; CAD: r=0.26, p<0.01), whereas no such correlation was recorded in controls (r=0.08). In conclusion, this study demonstrate an increased level of soluble AGE-IC in patients with CAD, either with or without diabetes, suggesting that AGE-IC might be involved in the atherosclerotic process, either as the result of it or as part of the pathophysiologic process.

Immune complexes; Coronary artery disease

nije evidentirano